PBE

Invesco Dynamic Biotechnology & Genome ETF

Up$52.39
+$0.07
(+0.13%)
As of 1:00:00 AM EDT | 2/20/19  |  Market Closed

PBE Trading Data

Open

$52.28

Low Price

$51.97

High Price

$52.5

Previous Last Price

$52.32

Bid Size

$0 X 0

Ask Size

$0 X 0

PBE Portfolio Data

AUM

$283,014,000

Shares

5,400

PE Ratio

68.98

Price / Book Ratio

6.1

Expense Ratio

0.59

Net Asset Value

$52.41

Volume

Volume

26,900

Avg. Volume (YDT)

29,394

Dollar Volume

$1,332,680

Weekly Avg. Volume

84,340

Monthly Avg. Volume

33,285

Quarterly Avg. Volume

31,180

PBE Fund Description

The Invesco Dynamic Biotechnology and Genome ETF is based on the Dynamic Biotech and Genome Intellidex Index. The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Index. The Intellidex Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value. The Underlying Intellidex Index is comprised of common stocks of 30 US biotechnology and genome companies. These are companies that are principally engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research. The Fund and the Index are rebalanced and reconstituted quarterly in February, May, August and November.

PBE Chart

PBE Summary

Fund Family

Invesco

Tracks This Index

Invesco Dynamic Biotechnology & Genome ETF

Inception Date

2005-06-23

Asset Class

Equity

Asset Class Size

Biotech

PBE Classification

Region (General)

North America

Region (Specific)

US

Sector

Health Care

Equity Index

Leveraged Family

PBE Holdings

Top 10 Holdings

Regeneron Pharmaceuticals Inc (REGN)
6.07%
QIAGEN NV (QGEN)
5.64%
Vertex Pharmaceuticals Inc (VRTX)
5.39%
Biogen Inc (BIIB)
5.24%
Neurocrine Biosciences Inc (NBIX)
5%
Gilead Sciences Inc (GILD)
4.99%
Amgen Inc (AMGN)
4.79%
Illumina Inc (ILMN)
4.57%
FibroGen Inc (FGEN)
3.89%
Enanta Pharmaceuticals Inc (ENTA)
3.5%

Total PBE Holdings

Total Holdings: 30

Regeneron Pharmaceuticals Inc (REGN)
6.07%
QIAGEN NV (QGEN)
5.64%
Vertex Pharmaceuticals Inc (VRTX)
5.39%
Biogen Inc (BIIB)
5.24%
Neurocrine Biosciences Inc (NBIX)
5%
Gilead Sciences Inc (GILD)
4.99%
Amgen Inc (AMGN)
4.79%
Illumina Inc (ILMN)
4.57%
FibroGen Inc (FGEN)
3.89%
Enanta Pharmaceuticals Inc (ENTA)
3.5%
Spark Therapeutics Inc (ONCE)
3.5%
Bio-Techne Corp (TECH)
3.31%
Exelixis Inc (EXEL)
3.18%
Cardiovascular Systems Inc (CSII)
3.09%
Genomic Health Inc (GHDX)
3.03%
Halozyme Therapeutics Inc (HALO)
3.02%
Catalent Inc (CTLT)
2.98%
United Therapeutics Corp (UTHR)
2.86%
Myriad Genetics Inc (MYGN)
2.76%
Emergent BioSolutions Inc (EBS)
2.59%
Repligen Corp (RGEN)
2.56%
Alkermes PLC (ALKS)
2.56%
Vanda Pharmaceuticals Inc (VNDA)
2.41%
PTC Therapeutics Inc (PTCT)
2.36%
WaVe Life Sciences Ltd (WVE)
2.28%
OPKO Health Inc (OPK)
2.21%
REGENXBIO Inc (RGNX)
2.16%
Sangamo Therapeutics Inc (SGMO)
2.07%
Acorda Therapeutics Inc (ACOR)
1.99%
PowerShares Dynamic Biotechnology & Genome Portfolio (PBE)
0%

PBE Technicals

Alpha

-9.01

Beta

1.42

Leverage

Long

Standard Deviation

4.12

PBE Dividends

Dividend Date

2018-09-24

Latest Dividend

0.002

Annual Dividend

0

Annual Dividend Rate

0

Annual Dividend Yield

1.0E-5

PBE Performance

YTD Return

11.3%

1 Year Return

2.48%

3 Year Return

40.04%

5 Year Return

16.04%

10 Year Return

320.47%

PBE Related Articles